CtDNA Positivity Linked to Worse Outcomes in Non-Small Cell Lung Cancer

A new comprehensive analysis of global research suggests that detecting circulating tumor DNA (ctDNA) in patients with non–small cell lung cancer (NSCLC) is linked to poorer outcomes, including reduced survival and a higher risk of cancer recurrence. However, the study, published in Translational Lung Cancer Research, also points to the potential for ctDNA testing to improve early detection and treatment strategies.

Evidence Gaps in NSCLC Prognosis

Despite advances in treatment, many patients with stage I to III NSCLC still experience disease progression and have low five-year survival rates. Current methods for monitoring treatment response, like imaging, don’t always align with findings from more invasive procedures. This highlights the need for non-invasive biomarkers that can accurately predict prognosis and guide treatment decisions.

Did You Know? The research encompassed studies published between January 2016 and May 2022, with data updated through June 2024.

ctDNA sequencing has emerged as a promising method for detecting minimal residual disease. These DNA fragments originate from tumor cells and carry specific genetic information. Researchers have noted ctDNA testing is highly sensitive, less repetitive, and more cost-effective than traditional approaches.

CtDNA Positivity and Patient Outcomes

The analysis included 52 studies, primarily conducted in China and the US, focusing largely on stage II and III NSCLC. The findings revealed that baseline ctDNA was associated with poorer relapse-free survival (RFS) across the overall NSCLC population (HR, 2.23). For patients with resectable NSCLC, detecting ctDNA immediately after surgery was strongly linked to worse RFS (HR, 5.64).

Following treatment, patients with positive ctDNA faced a significantly higher risk of recurrence, whether their cancer was resectable (HR, 5.82) or unresectable (HR, 2.72). This elevated risk persisted during long-term surveillance. CtDNA positivity was also consistently associated with poorer overall survival (OS) throughout the course of treatment, with baseline positive ctDNA predicting worse OS in both resectable (HR, 4.15) and unresectable (HR, 1.74) NSCLC.

Expert Insight: The consistent association between ctDNA positivity and poorer outcomes across multiple stages and time points underscores the potential for this biomarker to provide a more accurate and dynamic assessment of a patient’s disease status than traditional methods alone.

The increased risk of recurrence was observed across NSCLC subtypes. The median time between ctDNA detection and radiographic or clinical recurrence was 2.93 months.

Future Directions

The researchers acknowledged limitations, including variations across studies and the retrospective nature of many. They suggest that prospective trials with standardized methodologies are needed to confirm these findings and fully understand the clinical benefits of ctDNA testing. These trials could potentially refine risk stratification and guide individualized treatment decisions.

Frequently Asked Questions

What is ctDNA?

ctDNA are DNA fragments that originate from tumor cells and carry tumor-specific genetic information.

What stages of NSCLC were most commonly studied?

Most of the studies included in the analysis focused on stage II and III NSCLC.

What was the median time between ctDNA detection and recurrence?

Among studies enrolling at least 10 patients, the median interval between ctDNA detection and radiographic or clinical recurrence was 2.93 months.

As ctDNA testing becomes more refined, could it potentially lead to more personalized and effective treatment plans for individuals diagnosed with non-small cell lung cancer?